Green Cross to seek re-approval over human placenta injection

Green Cross Corporation said on March 26 that it will proceed to re-apply for its Greenpla, which was judged by the Korea Food and Drug Administration to be ineffective for treatment of climacteric disturbance.

According to the company, the product’s dosage administration will be changed from 2 weeks to 4 week, saying that 4 weeks of treatment have proven to be effective in the clinical sett...